Weston, FL – May 30th, 2018 – BiologicTx ®, a BioMatrix specialty pharmacy, announced today the release of MatchGrid with Lab Tools, a brand new product integrating transplant tissue typing data with advanced analytical tools to promote more successful Kidney Paired Donation (KPD) programs. The software makes it easier to analyze lab data and allows users to track a single antibody, or groups of antibodies over time.
BioMatrix Specialty Pharmacy Selected As Authorized Provider Of Vonvendi
BIOMATRIX SPECIALTY PHARMACY SELECTED AS AUTHORIZED PROVIDER OF VONVENDI
Agreement Enhances BioMatrix Product Offering to VWD Community
Media Contact: Tara Marchese
Corporate Director of Marketing
Tel: 954-908-7636
Email: tara.marchese@biomatrixsprx.com
FOR IMMEDIATE RELEASE
[DOWNLOAD PDF]
Weston, FL – May 2, 2018 – BioMatrix Specialty Pharmacy announced today their selection as an authorized provider of Shire’s limited distribution drug, Vonvendi™ [von Willebrand factor (Recombinant)]. Vonvendi is the first recombinant product indicated for on-demand treatment and control of bleeding episodes in adults diagnosed with von Willebrand disease (VWD). Von Willebrand disease is the most common bleeding disorder, affecting up to 1% of the US population. The chronic condition is caused by missing or dysfunctional von Willebrand Factor (VWF), leading to frequent recurring bleeding episodes.
Vonvendi is infused intravenously to replace missing or dysfunctional VWF. It is the first product to offer recombinant von Willebrand factor (rVWF) independent of recombinant Factor VIII (rFVIII). Shire reports this allows for a more tailored, patient specific treatment approach. Phase 3 open-label clinical study data demonstrated 100% treatment success using Vonvendi to control bleeding episodes.
“As a specialty pharmacy with extensive experience helping people with bleeding disorders effectively manage their condition, we are pleased to partner with Shire to offer Vonvendi,” said BioMatrix Chief Clinical Officer Marc Stranz. “We are committed to connecting patients with the products, resources and support to live a healthier life.”
To refer your patients to BioMatrix for Vonvendi therapy, please contact the pharmacy directly at 877-337-3002, online, or by completing a patient referral form. To review prescribing and other Vonvendi product information visit http://www.vonvendi.com.
About BioMatrix Specialty Pharmacy
BioMatrix Specialty Pharmacy offers comprehensive nationwide specialty pharmacy services and digital health technology solutions for a range of chronic health conditions including bleeding disorders, solid organ transplants, hepatitis C, HIV and more. Our growing family of companies unites leaders in the specialty pharmacy industry to improve health and empower patients to experience a higher quality of life. The current BioMatrix family of companies includes BiologicTx, Decillion Healthcare, Elwyn Pharmacy Group, Factor Support Network, Matrix Health, and Medex Biocare.
Factor Support Network Earns Perfect Score In Urac Specialty Pharmacy Accreditation
FACTOR SUPPORT NETWORK EARNS PERFECT SCORE IN URAC SPECIALTY PHARMACY ACCREDITATION
Second Member Of The BioMatrix Family Of Companies To Receive Perfect URAC Score Within Last 12 Months
Media Contact: Tara Marchese
Corporate Director of Marketing
Tel: 954-908-7636
Email: tara.marchese@biomatrixsprx.com
FOR IMMEDIATE RELEASE
[DOWNLOAD PDF]
Weston, FL – March 26, 2018 – Factor Support Network, a member of the BioMatrix family of companies, proudly announced today that it has received a 100% URAC Application Score with zero deficiencies for specialty pharmacy at its Camarillo, CA location. This reaccreditation marks the third perfect URAC assessment score for a BioMatrix company, and the second within the last 12 months. URAC is the independent leader in promoting healthcare quality through leadership, accreditation, measurement and innovation. Through reaccreditation, Factor Support Network has demonstrated a commitment to quality services, clinical expertise, and unsurpassed patient care.
“As a BioMatrix company, Factor Support Network is committed to providing pharmacy and support services helping patients achieve better health. URAC accreditation validates this commitment and represents our dedication to meeting and exceeding industry standards,” stated Bruce Greenberg, CEO at BioMatrix. "We applaud Factor Support Network on their achievement."
“It’s necessary for specialty pharmacies to provide a higher level of treatment for patients so desired outcomes are achieved. Factor Support Network shows a dedication to patient education and safety through the recognition of quality it received with URAC’s independent accreditation,” said URAC President and CEO Kylanne Green. “With URAC accreditation, people know that Factor Support Network strives to adhere to industry best practices.”
About Factor Support Network
Factor Support Network, a member of the BioMatrix family of companies, was founded in 1994 by families who were affected with chronic healthcare challenges with the goal to meet the diverse needs of families and persons facing lifelong illnesses such as hemophilia and von Willebrand Disease. We are committed to providing individualized, patient-focused services to people with bleeding disorders and other chronic conditions, nationwide. Our services promote better health through encouraging positive self-management and building a local network of support.
About BioMatrix SpRx
BioMatrix SpRx offers comprehensive nationwide specialty pharmacy services and digital health technology solutions for a range of chronic health conditions including bleeding disorders, solid organ transplants, hepatitis C, HIV and more. Our growing family of companies unites leaders in the specialty pharmacy industry to improve health and empower patients to experience a higher quality of life. The current BioMatrix family of companies includes BiologicTx, Elwyn Pharmacy Group, Factor Support Network, Matrix Health, and Medex Biocare.
About URAC
Founded in 1990, URAC is the independent leader in promoting healthcare quality through leadership, accreditation, measurement and innovation. URAC is a nonprofit organization using evidence-based measures and developing standards through inclusive engagement with a range of stakeholders committed to improving the quality of healthcare. Our portfolio of accreditation and certification programs span the healthcare industry, addressing healthcare management, healthcare operations, health plans, pharmacies, telehealth providers, physician practices, and more. URAC accreditation is a symbol of excellence for organizations to showcase their validated commitment to quality and accountability.
BioMatrix SpRx Selected as Authorized Provider of Hemlibra
BIOMATRIX SPRX SELECTED AS AUTHORIZED PROVIDER OF HEMLIBRA
First New Product for Hemophilia Inhibitor Patients in Nearly 20 Years
Media Contact: Tara Marchese
Corporate Director of Marketing
Tel: 954-908-7636
Email: tara.marchese@biomatrixsprx.com
FOR IMMEDIATE RELEASE
[DOWNLOAD PDF]
Weston, FL – December 14, 2017 – BioMatrix SpRx today announced they have been selected as an authorized specialty pharmacy provider of Genentech’s new drug, Hemlibra (emicizumab-kxwh). The product is indicated for pediatric and adult patients who have hemophilia A with inhibitors.
Receiving Breakthrough Therapy Designation by the FDA in 2015, Hemlibra is the first self-administered, subcutaneous therapy for hemophilia. Data from ongoing clinical studies indicates once weekly injections substantially reduce bleed rates. To review information regarding Hemlibra, including the full list of authorized providers, visit the Genentech Hemlibra webpage. www.hemlibra.com
Chief Clinical Officer David McCormick shares, “We are thrilled to partner with Genentech to offer Hemlibra. We have a long history of supporting patients with inhibitors and understand the unique challenges this community faces. We have witnessed the quality of life improvements this drug can provide, and are so proud to play our role in helping patients experience better health.”
To refer your patients to BioMatrix for Hemlibra therapy, please contact the pharmacy directly at 877-337-3002, online, or by completing a patient referral form.
About BioMatrix SpRx
BioMatrix SpRx, a portfolio company of Acon Investments and Triton Pacific Capital Partners, LLC., offers comprehensive nationwide specialty pharmacy services and digital health technology solutions for a range of chronic health conditions. Our growing family of companies unites leaders in the specialty pharmacy industry to improve health and empower patients to experience a higher quality of life. The current BioMatrix family of companies includes Matrix Health Group, Factor Support Network, Medex BioCare, BiologicTx, and Elwyn Pharmacy Group.
BIOLOGICTX® MATCHGRID POWERED LARGEST EVER KIDNEY EXCHANGE IN STATE OF CONNECTICUT AT YALE NEW HAVEN HOSPITAL
Totowa, NJ – August 18, 2017 – BiologicTx ®, a member of the BioMatrix SpRx family of companies, today announced that their kidney paired donation software, BiologicTx MatchGrid™, was the matching software utilized for a successful 9-way kidney exchange at the Yale New Haven Hospital beginning on May 9th and concluding on June 21st, 2017.
BIOLOGICTX® ANNOUNCES FIRST YEAR INTERNATIONAL TRANSPLANTATION SUCCESSES UTILITZING BIOLOGICTX MATCHGRID™
Totowa, NJ – May 1, 2017 – BiologicTx®, a member of the BioMatrix SpRx family of companies, today announced twelve-month International transplantation success statistics utilizing their Paired Donation Software, BiologicTx MatchGrid™.
BIOLOGICTX® EARNS PERFECT SCORE IN URAC ACCREDITATION IN SPECIALTY PHARMACY
Totowa, NJ – April 20, 2017 – BiologicTx®, a member of the BioMatrix family of companies,proudly announced today that it has received a perfect score and earned URAC accreditation in specialty pharmacy services for its Totowa, New Jersey facility.
BIOLOGICTX® ANNOUNCES ANOTHER SUCCESSFUL 6-WAY TRANSPLANT UTILIZING BIOLOGICTX MATCHGRID
Totowa, NJ – October 12, 2016 – BiologicTx® announced today, a successful, single-center, 6-way kidney transplant exchange at the Houston Methodist J.C. Walter Transplant Center in Houston, Texas.
BIOLOGICTX® DESENSITIZATION DATA SHOWS DECREASED TIME TO TRANSPLANT AND LOW RISK OF AMR POST-TRANSPLANT
Totowa, NJ – September 22, 2016 – BiologicTx® today announced their three year clinical transplant desensitization outcomes that demonstrate that desensitization with IVIg allows patients to reach transplant with a low risk of AMR and excellent allograft function, post-transplant.
BIOLOGICTX® ANNOUNCES INTERNATIONAL EXPANSION OF THEIR PAIRED DONATION SOFTWARE BIOLOGICTX MATCHGRID™
Totowa, NJ – June 28, 2016 – BiologicTx® today announced that their Paired Donation Software, BiologicTx MatchGrid™, has been implemented internationally at the King Faisal Specialist Hospital and Research Centre in Riyadh, Saudi Arabia under the supervision of Dr. Khalid Almeshari.
BIOLOGICTX® ANNOUNCES LAUNCH OF “KNOCKOUT AVOIDS” WITHIN BIOLOGICTX MATCHGRID™ 5.0 AT ATC BOOTH NUMBER 312
Totowa, NJ – June 10, 2016 – BiologicTx ® today announced the enhanced release of their Paired Donation Software, BiologicTx MatchGrid™ which includes a brand new feature called Knockout Avoids. Knockout Avoids provides virtual desensitization by simulating the removal of incompatible antibodies, which can be barriers to transplantation.
BIOLOGICTX® APPOINTS DR. ANDREA ZACHARY AND DR. MARY LEFFELL TO ITS MEDICAL ADVISORY BOARD AS CO-DIRECTORS OF SCIENCE FOR KIDNEY PAIRED DONATION
Totowa, NJ – January 5, 2016 – BiologicTx®, a transplant-focused specialty pharmacy, today appointed Andrea Z. Zachary, PhD, Diplomate, ABHI, and Mary S. Leffell, PhD, Diplomate, ABMLI, ABHI, to its Medical Advisory Board as Co-Directors of Science for the BiologicTx Kidney Paired Donation Program. In their new role, Drs. Zachary and Leffell will work with BiologicTx’s proprietary matching software, BiologicTx MatchGrid™ in several respects, including evaluating match runs between participating transplant centers, both domestically and internationally, and enhancing related software development.
BIOLOGICTX® IS A PROUD PHARMACY PROVIDER FOR ENVARSUS® XR
Totowa, NJ – December 1, 2015 – BiologicTx®, a transplant-focused specialty pharmacy, today announced that they have access to Veloxis Pharmaceuticals’ new product Envarsus® XR (tacrolimus extended-release tablets).
BIOLOGICTX EXPANDS NATIONAL FOOTPRINT WITH ACQUISITION OF SUNSHINE INFUSION SERVICES, INC.
Totowa, NJ – September 2, 2015 – BiologicTx® today announced the acquisition of Sunshine Infusion Services, Inc., in the greater Chicago, IL area.
BIOLOGICTX® ANNOUNCES FOUR-YEAR TRANSPLANT CLINICAL OUTCOMES DATA
Totowa, NJ – July 1, 2015 – BiologicTx® announced their four year transplant desensitization outcomes which demonstrated Continued Deceased Donor Desensitization Success.
BIOLOGICTX®‘s PAIRED DONATION SOFTWARE, BIOLOGICTX MATCHGRID™, ENABLES NINE-WAY, 36-HOUR PAIRED KIDNEY DONATION
Totowa, NJ – June 10, 2015 – BiologicTx® today announced that their Paired Donation matching software, BiologicTx MatchGrid™, was the driving force behind pairing up the eighteen donors and recipients in the nine-way kidney exchange that took place on June 4th and June 5th at Sutter Health’s California Pacific Medical Center (CPMC) and UCSF Medical Center. This is believed to be the first time a transplant event of this size was completed in the same city over a period of 36 hours.
BiologicTx® PAIRED DONATION’S MATCHGRID™ SOFTWARE POWERS 6-WAY SINGLE-CENTER TRANSPLANT CHAIN
Totowa, NJ – March 11, 2015 – BiologicTx® today announced that their Paired Donation Software, MatchGrid, was the platform responsible for matching up the donor and recipient pairs in the successful 6-way kidney paired donation transplant conducted at California Pacific Medical Center (CPMC) on March 5th and 6th, 2015. Initiated by an altruistic donor, this transplant marks the first successful single-center exchange of this magnitude on the West Coast.
BiologicTx® SELECTED AS THE SPECIALTY PHARMACY FOR PROSPECTIVE, GLOBAL, MULTI-CENTER, OBSERVATIONAL TREATMENT REGISTRY
Totowa, NJ – July 17, 2014 – BiologicTx® was selected as the specialty pharmacy for the observational treatment registry study to evaluate the long-term treatment effects of immune globulin intravenous (IGIV) maintenance therapy on donor specific antibodies (DSA) in renal transplant recipients. Study sponsors are Databean of Mount Vernon, NY and eMax Health of White Plains, NY.
BiologicTx® ACQUIRES INJECTABLE THERAPY SERVICES, INC., ESTABLISHING NATIONAL COVERAGE OF TRANSPLANT AND SPECIALTY PHARMACY SERVICES
Totowa, NJ – July 9, 2014 – BiologicTx® today announced the acquisition of Injectable Therapy Services, Inc., in Los Angeles, California, near the UCLA Campus. Injectable Therapy Services (ITS) provides solid organ transplant and other specialty pharmacy services nationally, including biologic, oral, and outpatient therapies through their Infusion Center and in the patient’s home.
BiologicTx® ANNOUNCES INITIATION OF OBSERVATIONAL CLINICAL STUDY FOR REGIONAL KIDNEY PAIRED DONATION USING DESENSITIZATION
Outcome Intended To Demonstrate Improvement in Overall Rate Of Kidney Transplantation in Sensitized Patients
Totowa, NJ – May 12, 2014 – BiologicTx® today announced the initiation of an observational clinical study to determine if a combination of desensitization and enrollment in a regional paired donor kidney (KPD) exchange program improves the overall rate of kidney transplantation in sensitized patients. This study is being conducted at five transplant centers in the Northwest region of the United States including: Swedish Medical Center, the University of Washington, Virginia Mason Medical Center, Oregon Health and Science University, and Providence Sacred Heart Medical Center and Children’s Hospital and is sponsored by BiologicTx®.
